Reuters exclusively reports J&J CEO pay irks investors upset with opioid lawsuits fallout

Reuters exclusively reported that Johnson & Johnson is coming under fire from some investors who are raising questions about companies that give their chief executives hefty pay raises despite facing billions of dollars in legal costs over their role in the U.S. opioid crisis. The Investors for Opioid & Pharmaceutical Accountability (IOPA), wrote to J&J’s board in January asking them to review their pay practices in light of the opioid litigation and agreed-to settlements, said Donna Meyer, director of shareholder advocacy at Mercy Investment Services Inc. to Reuters.